Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience
Authors
Keywords
Pancreatic ductal adenocarcinoma, Neoadjuvant therapy, Pancreatectomy, Pancreatoduodenectomy
Journal
JOURNAL OF GASTROINTESTINAL SURGERY
Volume 21, Issue 1, Pages 164-174
Publisher
Springer Nature
Online
2016-10-25
DOI
10.1007/s11605-016-3265-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma
- (2016) Jordan M. Cloyd et al. CANCER
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
- (2016) Matthew H. G. Katz et al. JAMA Surgery
- Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
- (2015) Li Liu et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
- (2015) Cristina R. Ferrone et al. ANNALS OF SURGERY
- The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy
- (2015) Christina L. Roland et al. ANNALS OF SURGICAL ONCOLOGY
- Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis
- (2015) Michael N. Mavros et al. ANNALS OF SURGICAL ONCOLOGY
- Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy
- (2015) Douglas B. Evans et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability
- (2015) Ronica H. Nanda et al. JOURNAL OF SURGICAL ONCOLOGY
- Has survival following pancreaticoduodenectomy for pancreas adenocarcinoma improved over time?
- (2015) Ahmed I. Salem et al. JOURNAL OF SURGICAL ONCOLOGY
- Two Thousand Consecutive Pancreaticoduodenectomies
- (2015) John L. Cameron et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer
- (2015) Fausto Petrelli et al. PANCREAS
- Improved Long-Term Outcomes After Resection of Pancreatic Adenocarcinoma: A Comparison Between Two Time Periods
- (2014) Pablo E. Serrano et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
- (2014) Marlo Blazer et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies
- (2014) Jeffrey M Sutton WORLD JOURNAL OF GASTROENTEROLOGY
- Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis
- (2013) Ching-Wei D. Tzeng et al. ANNALS OF SURGICAL ONCOLOGY
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
- (2013) Edward J. Kim et al. CANCER
- Clinical and Pathologic Features Influencing Survival in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Adenocarcinoma
- (2013) Cynthia E. Weber et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Trends in the Treatment of Resectable Pancreatic Adenocarcinoma
- (2013) Siavash Raigani et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
- (2013) Ching-Wei D. Tzeng et al. HPB
- Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
- (2012) Deyali Chatterjee et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma
- (2012) J. M. Pipas et al. ANNALS OF ONCOLOGY
- Pancreatic Ductal Adenocarcinoma
- (2012) Ioannis T. Konstantinidis et al. ANNALS OF SURGERY
- Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy
- (2012) Ching-Wei D. Tzeng et al. ANNALS OF SURGICAL ONCOLOGY
- Resection margin involvement and tumour origin in pancreatic head cancer
- (2012) C. S. Verbeke et al. BRITISH JOURNAL OF SURGERY
- Retroperitoneal Dissection in Patients with Borderline Resectable Pancreatic Cancer: Operative Principles and Techniques
- (2012) Matthew H.G. Katz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
- (2012) Ching-Wei D. Tzeng et al. HPB
- A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma
- (2012) Russell Lewis et al. HPB
- Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades
- (2011) Jordan M. Winter et al. ANNALS OF SURGICAL ONCOLOGY
- Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma
- (2011) Deyali Chatterjee et al. CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
- (2010) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer
- (2010) Klaus Sahora et al. SURGERY
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
- (2009) Christine A. Iacobuzio-Donahue et al. JOURNAL OF CLINICAL ONCOLOGY
- The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer
- (2009) Hartwig Riediger et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma
- (2008) Romuald Le Scodan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Anatomy of the Superior Mesenteric Vein With Special Reference to the Surgical Management of First-order Branch Involvement at Pancreaticoduodenectomy
- (2008) Matthew H. G. Katz et al. ANNALS OF SURGERY
- Development of an Integrated Biospecimen Bank and Multidisciplinary Clinical Database For Pancreatic Cancer
- (2008) Rosa F. Hwang et al. ANNALS OF SURGICAL ONCOLOGY
- Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Gauri R. Varadhachary et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search